Thoughts on ACUS
Take a look at the following article from MSN dated August 17th, research by Zach’s; it’s what drew my attention to this stock. I don’t believe the initial Phase III trails were totally successful, so I’ve held off buying. I may throw $500 at it with a stop/loss and see what happens. The nice thing about Imagify is there is no radioactivity, so less overall expense to hospitals.
https://news.moneycentral.msn.com/ticker/article.aspx?Feed=BW&Date=20070813&ID=7316413&Symbol=ACUS
It's been a little less than four months since the RAMP-2 data came out, and Acusphere ACUS shares are down 65% since then. Wall Street clearly thinks the company's drug Imagify has little chance for approval. In the meantime, cash burn is a concern and management is going to have to figure out how to raise money yet again in 2008. As a result, the Street views ACUS like a sinking ship.
With all that said, the opinion of medical and echo-cardiology community couldn't be more different from that of Wall Street. Cardiologists are excited about the data and the clear majority expects the use the drug immediately upon approval. Why is there such a split opinion, and who is right?
It is clear to us that this drug works, and is an extremely useful tool in the diagnosis of coronary artery disease (CAD). Looking at the tapes we quickly forgot about the botched trial endpoints, the dilutive offerings, and the mismanaged expectations of Wall Street. What we saw was powerful - a drug that really does do what it says, regardless of the statistical rigmarole.
Take a look at the following article from MSN dated August 17th, research by Zach’s; it’s what drew my attention to this stock. I don’t believe the initial Phase III trails were totally successful, so I’ve held off buying. I may throw $500 at it with a stop/loss and see what happens. The nice thing about Imagify is there is no radioactivity, so less overall expense to hospitals.
https://news.moneycentral.msn.com/ticker/article.aspx?Feed=BW&Date=20070813&ID=7316413&Symbol=ACUS
It's been a little less than four months since the RAMP-2 data came out, and Acusphere ACUS shares are down 65% since then. Wall Street clearly thinks the company's drug Imagify has little chance for approval. In the meantime, cash burn is a concern and management is going to have to figure out how to raise money yet again in 2008. As a result, the Street views ACUS like a sinking ship.
With all that said, the opinion of medical and echo-cardiology community couldn't be more different from that of Wall Street. Cardiologists are excited about the data and the clear majority expects the use the drug immediately upon approval. Why is there such a split opinion, and who is right?
It is clear to us that this drug works, and is an extremely useful tool in the diagnosis of coronary artery disease (CAD). Looking at the tapes we quickly forgot about the botched trial endpoints, the dilutive offerings, and the mismanaged expectations of Wall Street. What we saw was powerful - a drug that really does do what it says, regardless of the statistical rigmarole.
Hot Forum Topics
-
Monday 9/14/2026
680
-
Serious Streak Survivor Strategies
1,918,134
-
Couple Beers
2,176
-
I'm embarrassed for Trump supporters
57,688
-
NFL LOCKED IN!
97,196
-
Trump's legacy?
25,416
-
Week One-Post Week One Plays Here
1,861
-
DEN/KC live in game comments welcome
719
-
Betting NFL isnt the same anymore Tapping out.
1,329
-
PART DEUX
139
Warning - External Link
Report User
This post is spam
Delete Post
Remove Thread
Scan Results
Login/Register
Accounts are free and easy to create.
Search
